Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dipna PharmachemBOM:543594 +9.64%62 Gross Margin % is 2.27% as of Mar. 2026, which is 55% below its 10-year median of 5.10. GuruFocus rates BOM:543594 with a GF Score™ of 62/100 and a GF Value™ of ₹9.16 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 627 Healthcare Providers & Services companies, Dipna Pharmachem ranks worse than 96.49% on this metric.
The historical rank and industry rank for Dipna Pharmachem's Gross Margin % or its related term are showing as below:
BOM:543594'
s Gross Margin % Range Over the Past 10 Years
Min: 3.91 Med: 5.1 Max: 16.73
Current: 8.96
During the past 7 years, the highestGross Margin % of Dipna Pharmachem was 16.73%. The lowest was 3.91%. And the median was 5.10%.
BOM:543594's Gross Margin % is ranked worse than 96.49% of 627
companies
in the Healthcare Providers & Services industry
Industry Median: 40.06
vs BOM:543594: 8.96
Dipna Pharmachem had a gross margin of 2.27% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Dipna Pharmachem was 20.40% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Dipna Pharmachem had a gross margin of 2.27% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Dipna Pharmachem Gross Margin % Related Terms
Dipna Pharmachem Gross Margin % Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Dipna Pharmachem (BOM:543594) has a Gross Margin % of 2.27% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Dipna Pharmachem and its competitors. This is 55% below median its historical median of 5.10. Over the past decade, Dipna Pharmachem's Gross Margin % has ranged from 3.91 to 16.73. According to the industry distribution chart, Dipna Pharmachem ranks #605 out of 627 companies in the Healthcare Providers & Services industry, placing it in the top 96.5%.
Is Dipna Pharmachem's Gross Margin % too high?
Dipna Pharmachem's current Gross Margin % of 2.27% is 55% below median its 10-year median of 5.10. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 16.73. The Healthcare Providers & Services industry median Gross Margin % is 40.06. Dipna Pharmachem's value of 2.27% is 94.3% below this industry median. Based on the distribution chart, Dipna Pharmachem ranks #605 out of 627 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's Gross Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #605 out of 627 companies for Gross Margin %. This places Dipna Pharmachem in the lower half of its industry. The industry median Gross Margin % is 40.06. Dipna Pharmachem's value of 2.27% is 94.3% below this benchmark. Historically, Dipna Pharmachem's own Gross Margin % has ranged from 3.91 to 16.73 over the past decade. While the company's 10-year median is 5.10 vs. the industry median of 40.06, Dipna Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.06, based on 627 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dipna Pharmachem's current Gross Margin % of 2.27% is 94.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current Gross Margin % is 2.27%, which is 55% below median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹9.16, compared to a current price of ₹4.89 — trading 46.6% below its estimated fair value. The current Gross Margin % is 2.27%, which is 55% below median its 10-year median of 5.10 and 94.3% below the Healthcare Providers & Services industry median of 40.06. Dipna Pharmachem's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current Gross Margin % is 2.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.89 is trading 46.6% below its estimated GF Value™ of ₹9.16.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
Gross Margin %: 2.27% (55% below median its 10-year median of 5.10)
GF Value™: ₹9.16 vs. price of ₹4.89 (46.6% below fair value)
Industry Position: 94.3% below the Healthcare Providers & Services median (#605 of 627)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
62GF Score
Get the complete analysis for BOM:543594
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
